Amivantamab for advanced non-small-cell lung cancer

featured image
Therapeutic Areas: Lung and Respiratory Cancer
Year: 2021

Amivantamab is in clinical development in the treatment of patients with advanced non-small-cell lung cancer (NSCLC) who have previously been treated with platnum-based chemotherapy. NSCLC makes up the majority of lung cancers in the UK. Metastatic NSCLC is when the cancer has spread beyond the lung that was initially affected, most often to the liver, the adrenal glands, the bones, and the brain. Most patients with NSCLC are diagnosed at the advanced/metastatic stage where curative treatment with surgery is unsuitable.
Amivantamab is an intravenously administered drug that can bind to both EGFR and another receptor that helps tumours grow, hepatocyte growth factor receptor (cMet). Binding to these receptors slows tumour growth by stopping them receiving signals and making them a target to be brokendown and destroyed by for immune cells. If licenced amivantamab will provide a treatment for patients with advanced NSCLC who have previously been treated with platnum-based chemotherapy, who have limited therapies available.